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Efficacy of High-dose Chemotherapy and Autologous Stem Cell 
Transplantation in Patients with Relapsed Medulloblastoma: A 
Report on The Korean Society for Pediatric Neuro-Oncology 
(KSPNO)-S-053 Study
The efficacy and toxicity of high-dose chemotherapy and autologous stem cell 
transplantation (HDCT/ASCT) were investigated for improving the outcomes of patients 
with relapsed medulloblastoma. A total of 15 patients with relapsed medulloblastoma 
were enrolled in the KSPNO-S-053 study from May 2005 to May 2007. All patients 
received approximately 4 cycles of salvage chemotherapy after relapse. Thirteen 
underwent HDCT/ASCT; CTE and CM regimen were employed for the first HDCT (HDCT1) 
and second HDCT (HDCT2), respectively, and 7 underwent HDCT2. One transplant 
related mortality (TRM) due to veno-occlusive disease (VOD) occurred during HDCT1 
but HDCT2 was tolerable with no further TRM. The 3-yr overall survival probability and 
event-free survival rates ±95% confidence intervals (CI) were 33.3±12.2% and 26.7% 
±11.4%, respectively. When analysis was confined to only patients who had a complete 
response (CR) or partial response (PR) prior to HDCT, the probability of 3-yr overall 
survival rates ±95% CI was 40.0±15.5%. No patients with stable disease (SD) or 
progressive disease (PD) survived. Survival rates from protocol KSPNO-S-053 are 
encouraging and show that tumor status prior to HDCT/ASCT is an important factor to 
consider for improving survival rates of patients with relapsed medulloblastoma.
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INTRODUCTION
The survival rate of those with relapsed brain tumors remains 
poor although treatment methods have been improved by mul-
timodality treatment, radiotherapy and chemotherapy, with 
surgery (1, 2). Intrinsic chemo-resistance of relapsed tumors 
and previous radiotherapy limit treatment options at the time 
of relapse. High-dose chemotherapy (HDCT) and autologous 
stem cell transplantation (ASCT) have recently been applied in 
patients with relapsed brain tumor in order to overcome these 
obstacles, eradicate residual tumor cells, and extend survival (3, 
4). Single transplantation had been known as a potentially cu-
rative method in many high-risk and relapsed central nervous 
system (CNS) tumors. Tandem transplantation for treatment of 
pediatric solid tumors such as high-risk neuroblastoma and 
retinoblastoma has been tried (5, 6). Tandem transplantation in 
cases of relapsed CNS tumors has also been attempted but the 
effectiveness of this therapy has not been proven (7). The Kore-Park JE, et al.  •  Autologous Stem Cell Transplantation for Relapsed Medulloblastoma
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an Society of Pediatric Neuro-Oncology (KSPNO) established 
the protocol KSPNO-S-053 to treat children with relapsed brain 
tumor diagnosed as medulloblastoma in an effort to improve 
the survival of pediatric patients treated with HDCT/ASCT in-
cluding tandem transplantation. 
MATERIALS AND METHODS
Patient enrollment 
This study included patients under 25 yr of age who had relapsed 
CNS tumors diagnosed as medulloblastoma between May 2005 
and May 2007. These patients had been treated with various 
chemotherapies, surgery, or radiotherapy prior to relapse. Re-
lapsed tumors were diagnosed by pathology after surgery, radio-
logical study, and/or cerebrospinal fluid examination. Patients 
who underwent previous stem cell transplantation were exclud-
ed. A total of 16 patients were initially enrolled in the KSPNO-
S-053 protocol. A case that had violation without using salvage 
regimens recommended by this protocol was excluded during 
the course of review leaving 15 patients. This protocol was ap-
proved by each hospital’s institutional review board and inform-
ed consent was obtained from parents or guardians of all pa-
tients (IRB No. H-0808-025-253). Analysis was completed on 13 
of 15 patients who were able to do HDCT/ASCT including tan-
dem transplantation. 
Treatment
Pre-HDCT treatment and tumor status 
Following a diagnosis of relapsed medulloblastoma, patients 
were treated by surgery, radiotherapy if possible, and salvage 
chemotherapy (SC). The KSPNO-S-053 protocol recommended 
SC, alternating regimens A and B for 4 cycles; however, applica-
tion of these regimens was not mandatory. Regimen A consists 
of: cisplatin 60 mg/m
2/day on day 0; etoposide 50 mg/m
2/day, 
days 0, 1, and 2; cyclophosphamide 750 mg/m
2/day, days 1 and 
2; and vincristine 1.5 mg/m
2/day days 0 and 7. Regimen B con-
sists of: carboplatin 200 mg/m
2/day, days 0 and 1; etoposide 50 
mg/m
2/day, days 0, 1, 2, 3, and 4; ifosfamide 750 mg/m
2/day, 
days 0, 1, 2, 3, and 4; and vincristine 1.5 mg/m
2/day, days 0 and 7. 
Other generally accepted chemotherapy agents could be added 
to the recommended SC or the dose of recommended SC drugs 
could be modified according to physicians’ choice to avoid the 
toxicity derived from overlapping chemotherapy drugs when 
similar drugs were used prior to relapse. The goal of SC was to 
minimize tumor burden prior to HDCT so that tumor status 
could be considered as having complete response (CR) or par-
tial response (PR) before HDCT1. For this reason, the numbers 
of cycles of SC could be added or abstracted. After HDCT1, if 
the tumor status shows CR, tandem transplantation was option-
al; but in the case of PR or stable disease (SD), tandem transplan-
tation was obligatory, and if progressive disease (PD) was the 
result, the recommendation was to go off therapy (Fig. 1). 
HDCT/ASCT
All participants followed the protocol for conditioning regimens; 
however, it was optional whether a patient proceeded to tandem 
HDCT/ASCT if tumor status was CR after HDCT1 but obligato-
ry if status indicated PR. The HDCT1 was administered with CTE 
regimen (carboplatin 500 mg/m
2/day, day -8, -7, -6; thiotepa 
300 mg/m
2/day, day -5, -4, -3; etoposide 250 mg/m
2/day, day 
-5, -4, -3). HDCT2 was administered with CM regimen (cyclo-
phosphamide 1,500 mg/m
2/day, day -8, -7, -6, -5; mephalan 60 
mg/m
2/day, day -4, -3, -2). An interval 12 weeks was recom-
mended between HDCT1 and HDCT2. The patients received 
standard supportive care according to the physicians’ discre-
tion at each hospital following HDCT. No additional tumor-di-
rected therapy was given after ASCT unless there were further 
residual or recurrent tumors.
Collection of peripheral blood stem cells (PBSC)
If the absolute neutrophil count (ANC) became higher than 
500/ μL after the first SC cycle, granulocyte colony stimulating 
factor (G-CSF) 10 μg/kg/day was injected subcutaneously until 
the morning of the last day of leukapheresis for mobilization of 
PBSC collection. Leukapheresis was initiated when the white 
blood cell count was beyond 1,000/μL and monocytes in pe-
ripheral blood were ready to appear. The aim was to collect 
more than 5×10
6 CD34
+ cells per kg of PBSC for use in 2 rounds 
of ASCT because of the possibility of tandem transplantation.
Definitions
Neutrophil engraftment was defined as the first day when neu-
trophil counts rose from trough to 500/μL or above for 3 con-
secutive days. Platelet engraftment was defined as having risen 
above 20,000/μL without platelet transfusion for 7 consecutive 
days. CR was defined as resolution of all initially demonstrable 
tumors without appearance of new areas of disease. PR was de-
fined as greater than a 50% decrease in the product of the 2 larg-
Relapsed medulloblastoma
Salvage chemotherapy: try to minimize tumor size
pre-HDCT evaluation
1st HDCT and ASCT
post-1st HDCT and ASCT evaluation
CR: 2nd HDCT is optional
PR or SD: 2nd HDCT is recommended
PD: off therapy
Fig. 1. Overview of KSPNO-S-053 protocol for relapsed medulloblastoma.
CR, complete response; PR, partial response; PD, progressive disease; SD, stable 
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est perpendicular tumor diameters, SD as less than a 50% de-
crease and PD as greater than a 25% increase.
Toxicity and survival analysis
Grading of toxicity was based on the National Cancer Institu-
tion Common Toxicity Criteria. Event-free survival (EFS) was 
considered from the date of diagnosis of a relapsed tumor to 
the date of disease relapse or progression or treatment related 
mortality (TRM), whichever came first. The overall survival (OS) 
was assessed from the date of diagnosis of a relapsed tumor to 
the date of death. Both EFS and OS rates were estimated using 
the Kaplan–Meier method and were compared using the log-
rank test. Continuous variables in the 2 groups were compared 
using the Mann–Whitney U test. Statistical significance was ac-
cepted as P<0.05. Statistical software R was used to conduct the 
entire survival analyses. 
RESULTS
Patient characteristics
Fifteen pediatric patients, 10 males and 5 females, diagnosed as 
having relapsed medulloblastoma were enrolled in the KSPHO-
S-053 protocol. The mean age of the patients at the time of diag-
nosis of tumor relapse was 10.9 (range: 2-23) yr. All patients re-
ceived a median 5 (range: 2-7) cycles of salvage chemotherapy 
(Table 1). All patients received regimen A or B (or B+) to mini-
mize the toxicity of chemotherapeutic drugs used before their 
tumor relaps  ed, according to their physician’s discretion. Seven 
patients received regimen (B+) containing irinotecan, modified 
on the basis of regimen B. Two patients could not receive HDCT: 
patient #12 experienced rapid progression of disease during SC 
so his general condition did not permit HDCT, and patient #8 
died due to sepsis in a neutropenic condition during SC. Thir-
teen patients received HDCT with single or tandem ASCT; 7 re-
ceived tandem transplantation and 6 received single transplan-
tation. In the case of the 7 tandem transplantations, the period 
between HDCT1 and HDCT2 was median 105 (range 83-119) 
days.
Stem cell collection
Hematopoietic stem cells were mobilized and collected in all 
14 patients who completed the first cycle of SC. The source of 
hematopoietic stem cells was peripheral blood in all patients, 
collected during a median 2 rounds of leukapheresis (range 
1-4). The median of the collected total nucleated cells (TNC) 
and CD34
+ cells were 12.2 (range 3.0-37.5)×10
8 cells/kg and 13.5 
(range 4.6-134.3)×10
6 cells/kg, respectively. 
Hematologic recovery
The median day of hematologic recovery after HDCT1, which 
required reaching an ANC over 500/μL and a platelet count over 
20,000/μL without transfusion was 10 days (range 8-20) and 19 
days (range 13-66), respectively. In patients who had undergone 
tandem transplantation, the median time of neutrophil and plate-
let count recovery after HDCT2 was 9 days (range 8-10) and 18 
days (range 14-29), respectively (Table 2).
Toxicity 
In this study, 2 patients died of TRM. Patient #8 died due to sep-
sis in a prolonged neutropenic state after the second cycle of SC. 
The other patient, #14, died of veno-occlusive disease (VOD) 
with septic shock during HDCT1 followed by ASCT. The most 
Table 1. Characteristics of patients with relapsed medulloblastoma (N=15)
Pt. 
No.
Sex/ 
Age
(yr)
Treatment 
before
relapse
Site of
relapse
Surgery or RT
after relapse
Salvage
Chemotherapy 
before HDCT1
Status
before
 HDCT1
Status
after
HDCT1
No. 
of
HDCTs
Status
after
HDCT2
EFS
(m)
OS
(m)
Current status
  1 M/5 S, RT, CT p, m (M2) - B (7) CR CR 1 - 18 24 Dead (Ds progression)
  2 M/5 S, CT p, m (M3)     RT (36/19.8/0) A (3), B (3) CR CR 2 CR    38+    38+ Alive (Ds free)
  3 M/22 S, RT, CT p, m (M3) RT (0/0/24) B (4), A (2) CR CR 1 - 19 37 Dead (Ds progression)
  4 M/15 S, RT, CT p, m (M2) - B (5) PR PR 1 - 11 18 Dead (Ds progression)
  5 M/9 S, RT, CT p - A (2), B (2) SD SD 2 SD   7 11 Dead (Ds progression)
  6 F/19 S, RT, CT p, m (M3)    RT (19.8/0/0) A (1), B (1) PR CR 2 CR    38+    38+ Alive (Ds free)
  7 M/8 S, RT, CT p, m (M3) RT (18/0/0) A (3) PD PR 2 PD   8   9 Dead (Ds progression)
  8 M/19 S, RT, CT p RT (15/0/0) A (1), B (1) TRM - 0 -   1   1 Dead (Sepsis)
  9 F/23 S, RT, CT p, m (M2) STR A (1), B+ (3) CR CR 1 -    35+    35+ Alive (Ds free)
10 M/10 S, RT, CT p, m (M3) - A (2), B (1), B+ (1) PR CR 2 CR 16 21 Dead (Ds progression)
11 M/9 S, RT, CT p, m (M3) STR A (1), B+ (4) PD PR 2 PR 16 17 Dead (Ds progression)
12 M/9 S, RT, CT p, m (M2) - A (2), B+ (3) PD - 0 -   6   7 Dead (Ds progression)
13 F/2 S, CT p RT (23.4/18/0) A (2), B (2), B+ (1) PR CR 2 CR    44+    44+ Alive (Ds free)
14 F/11 S, RT, CT p, m (M3) - A (2), B (1), B+ (2) PR TRM 1 - 12 12 Dead (VOD at HDCT1)
15 F/8 S, RT, CT p, m (M3) - A (2), B (4) PR PD 1 - 11 18 Dead (Ds progression)
Pt. No., patient number; m, months; HDCT1, first high-dose chemotherapy; HDCT2, second HDCT; EFS, event free survival after relapse; OS, overall survival after relapse; S, 
surgery; RT, radiotherapy; CT, chemotherapy; p, primary site; m, metastatic site; Ds, disease; STR, subtotal resection; TRM, treatment related mortality; Radiation dose (Gy) for 
RT(craniospinal/primary/metastatic site); A, regimen A; B, regimen B; B+, modified regimen B including irinotecan. Park JE, et al.  •  Autologous Stem Cell Transplantation for Relapsed Medulloblastoma
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frequently developed grade 3 and 4 toxicities in 20 HDCTs were 
fever, stomatitis, diarrhea, elevated liver enzymes, and hyper-
bilirubinemia in order of frequency. There were no TRMs in the 
7 patients who underwent HDCT2 (Table 2).
EFS and OS rate 
Three year OS and EFS rates of the total 15 patients from the time 
of relapse, were 33.3±12.2% and 26.7±11.4%, respectively (Fig. 
2A). Of the 15 patients, 2 could not received HDCT(s) because 1 
patient had rapidly progressive disease without preparing to do 
HDCT, and another patient died of sepsis during the period of 
SC. The 3-yr OS rate of the 13 patients who underwent HDCT(s) 
was 28.8±13.1% with a median follow-up of 21 months (range 
9-44) after diagnosis of tumor relapse. Four patients are alive 
and event-free at 35, 38, 39 and 44 months since diagnosis of a 
relapsed tumor. Of 9 patients who had events, 8 experienced re-
lapse or progression since HDCT1, and another had TRM at the 
time of HDCT1 and ASCT. Three-year EFS rates for these patients 
was 30.8±12.8% with a median follow-up of 16 months (range 
7-44) after the diagnosis of relapsed tumor (Fig. 2B). There were 
no statistical differences in survival rates between the 2 groups 
of patients who received tandem (7 patients) or single (8 patients) 
transplantation (data not shown).
Responses and survivals according to disease status prior 
to HDCT1
Of the 13 patients who underwent transplantation, there were 4 
CRs, 6 PRs, 2 PDs and 1 SD pre-HDCT following SC. Three-year 
OS rates of 10 patients with status pre-HDCT of CR or PR was 
40±15.5% with a median of 21 months (range 1-38) from HDCT1 
(Fig. 2C), but 3 patients with SD or PD died due to disease pro-
gression with a median survival period of 7.5 months (range 
6-16). 
  Of 4 patients with CR status pre-HDCT: one patient #2, who 
received optional HDCT2 and achieved CR status after HDCT1 
as well as HDCT2, is alive. Another 3 patients, #1, #3 and #9, re-
ceived single transplantation and maintained CR status after 
HDCT1 but 2 of them eventually experienced disease progres-
sions to death leaving only 1 alive. 
Fig. 2. (A) Event free and overall survival of all patients at 3 year survival from diagnosis of relapsed tumor (n=15). (B) Event free and overall survival of the patients who received 
HDCT from when diagnosis of relapsed tumor (n=13). (C) Overall survival of the patients who received HDCT in pre-HDCT CR or PR status vs. SD or PD status from 1st HDCT 
(n=10). 
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Table 2. Characteristics of patients who underwent HDCT/ASCT (N=13)
Variables
1st ASCT (n=13)
Median (Range)
2nd ASCT (n=7)
Median (Range)
Infused cells
   TNCs
   CD34 cells
7.9 (1.9-16.5)
7.0 (3.5-44.5)
8.9 (0.1-21.8)
9.5 (8.0-55.4)
Hematologic recovery
   Days to reach an ANC 500/µL
   Days to reach a PLT count 20,000/µL
10 (8-20)
  19 (13-66)
9 (8-10)
18 (14-29)
Grade 3 or 4 toxicity 
   Microbiologically documented infection
   Presence of high fever (>38.5˚C)
   Duration (days) of high fever
   Vomiting
   Stomatitis
   Diarrhea
   Elevation of liver enzyme
   Total bilirubin (>3 mg/dL)
   Veno-occlusive disease
   Elevation of serum creatinine
   Hyponatremia
  2
13
4 (1-11)
  3
  8
  7
  4
  4
  3
  3
  1
1
6
2.5 (1-11)
2
2
1
1
0
1
0
0
Treatment related mortality   1 0
TNC, Total number of cells (×10
8/kg).
CD34
+ cells (×10
6/kg).
Fig. 3. Study progression following salvage chemotherapy (n=13). 
*2nd HDCT was refused by a patient’s guardian. 
CR, complete response; PR, partial response; PD, progressive disease; SD, stable 
disease.
1st HDCT 2nd HDCT
4 1
6
3
3
3
CR (4) CR (4)
CR (3)
CR (1)
PR (6)
PD (2) 
SD (1)
CR (3)
 PR (1)*
PD (1)
TRM (1)
PR (2)
SD (1)
CR (3)
PR (1), PD (1)
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  Of 6 patients with PR status pre-HDCT: 3 achieved CR status 
after HDCT1 and received optional HDCT2; 2 patients, #6 and #13 
maintain CR status and are still alive. Patient #4, who achieved 
PR status after HDCT1 did not receive HDCT2 because the pa-
tient’s guardian refused tandem transplantation. The disease of 
patient #15 progressed so he could not receive tandem trans-
plantation, and patient #14 died of TRM at HDCT1 and ASCT 
(Fig. 3). These 3 patients who did not receive HDCT2 all died. 
The patients who were at PR status pre-HDCT could achieve 
long-term survival but patients who could not receive tandem 
transplantation died. 
  Three patients, 2 with PD and 1 with SD pre-HDCT that un-
derwent HDCT2, all died of disease progression. 
Survival analysis according to tumor responsiveness after 
1st HDCT/ASCT
With the exception of 1 patient who died of TRM, 5 patients who 
could not reach CR status died due to disease progression or 
relapse irrespective of disease status after HDCT1. However, of 
7 patients who reached CR after HDCT1, 3 of 4 who underwent 
tandem transplantation (4 optional indications) are alive, and 
only 1 of 3 (3 optional indications) who did not undergo tandem 
transplantation is alive, disease-free. This patient was in PR pre-
HDCT, underwent SC, and achieved CR status after HDCT1, 
indicating that a second round of HDCT/ASCT might be help-
ful to patients who show a response to high-dose chemothera-
py during HDCT1/ASCT.
DISCUSSION
Children with relapsed medulloblastoma have a dismal outcome 
with standard or alternative treatments (1). Two-year survival 
rates for relapsed medulloblastoma were reported to be below 
20% (8). Recently, sequential cycles of dose-intensive chemo-
therapy or tandem transplantation have been tried in the treat-
ment of chemo-sensitive high-risk or recurrent brain tumors, 
including recurrent medulloblastoma (9-11). The survival rate 
was reported as a broad range, 5-54%, by studies done in vari-
ous different situations with regard to pre-transplant conven-
tional chemotherapy, conditioning regimens, disease status 
prior to HDCT, and adjuvant therapy. Some studies did not sep-
arate recurrent medulloblastoma from high-risk medulloblas-
toma or other brain tumors types in their study group (8, 12). 
Grururangan et al. (13) reported a 3-yr overall survival rate of 
14% in recurrent medulloblastoma patients who underwent 
HDCT/ASCT and received no irradiation before relapse, while 
no survival was found in those who underwent HDCT/ASCT 
receiving irradiation before relapse and in those who did not 
undergo HDCT/ASCT and received only standard SC. Our study, 
focusing on relapsed medulloblastoma, showed a 3-yr EFS and 
3-yr OS of 31% and 29%, respectively (Fig. 2). 
  A few reports have shown that pre-HDCT disease status is 
most important when it comes to predicting survival rates in 
relapsed or high-risk brain tumor cases. The survival rate is high-
est in patients with previous CR status and less high in patients 
with minimal residual disease, but nearly absent in patients with 
bulky disease before ASCT (2, 10). Therefore, some reports that 
studied patients with relapsed brain tumor focused mainly on 
those with a PR or CR disease status prior to HDCT (10, 14). How-
ever, our study included data of PD or SD status, as well as CR 
or PR status, prior to HDCT1. In our study, the 3-yr OS rates in 
patients with PR or CR status prior to HDCT was 40%, compared 
to no survival in patients with PD or SD status (Fig. 2C). 
  Most recent reports of high-risk or relapsed brain tumors 
treated with HDCT/ASCT at CR status show favorable survival 
rates. Fagioli et al. (12) reported that patients with CR status fol-
lowing a poor prognosis brain tumor had a survival rate of 50.6% 
compare to 19.6% for those without CR status. Cheuk et al. (14) 
reported that long-term survival in CR patients before HDCT was 
63% (5 out of 8 CR patients survived), but that 5 PR patients all 
died in the study of single transplantation in high-risk or recur-
rent CNS tumors. In our study, 4 patients who had both local 
and disseminated relapsed tumors achieved CR status at the 
time of their HDCT1. Two survived and were disease free with 
a 3-yr EFS rate of 50%. Relapsed patients with a previous CR 
status after multimodality salvage therapy, treated with HDCT/
ASCT, are curable. 
  Some studies reported that patients with PR status before 
HDCT would die eventually from PD since the treatment of 
HDCT cannot eradicate their residual malignancies (12). The 
recent study by Cheuk et al. reported that 5 patients with PR dis-
ease status before HDCT, who had a median 8-month disease 
free period, did not survive a long-term (12, 14). However some 
researchers suggest that using multiple sequential intensive ther-
apy or tandem transplantation has some benefit in this disease 
status before HDCT, because a single application of HDCT can-
not eradicate the disease (9). Sung et al. (10) reported that of 9 
patients with PR status before HDCT, whose tumors were high-
risk or relapsed medulloblastoma and supratentorial primitive 
neuroectodermal tumor, 8 who received tandem transplanta-
tion were alive with a median follow-up of 18 month and 7 of 
those were disease free. In our study, 6 patients had PR status 
pre-HDCT; of those, 2 of 3 patients who received tandem trans-
plantation were alive and disease free (44 and 38 months), but 
3 patients who did not receive tandem transplantation died. 
These results show that tandem transplantation has the possi-
bility of prolonging survival of relapsed pediatric medulloblas-
toma patients with PR status in response to upfront chemother-
apy. In the future the role of tandem transplantation may need 
to be defined for patients with a status of PR after upfront che-
motherapy before HDCT.
  Of the total 15 patients, 4 who had no response or disease Park JE, et al.  •  Autologous Stem Cell Transplantation for Relapsed Medulloblastoma
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progression during the period of upfront SC died, although 3 
were treated with tandem transplantation. Some other studies 
concerning the treatment of recurrent brain tumors using sin-
gle or tandem transplantation showed similar results. Because 
the relapsed tumors achieved only PR or SD status after SC with 
or without surgery or irradiation, patients with PR or SD status 
at HDCT1 were not able to be cured with HDCT/ASCT, even 
with tandem transplantation. 
  Surgery, radiotherapy, and SC are common treatment meth-
odologies used to reduce tumor burden prior to HDCT. Children 
diagnosed with relapsed medulloblastoma who were radiother-
apy naïve and chemo-responsive were able to be cured. Buttur-
ini et al. (7) reported the 3-yr post-transplant EFS rate in unirra-
diated versus previously irradiated children to be 83% vs. 20% 
respectively, using a thiotepa based conditioning regimen. Our 
study had a similar result for 2 patients newly diagnosed before 
3 yr of age who were unirradiated before relapse. These 2 pa-
tients, #2 and #13, received craniospinal irradiation following 
relapse and then received tandem transplantation and are now 
surviving disease-free. 
  Our study had 1 patient who died of VOD with sepsis at HDCT1 
and ASCT, resulting in a TRM rate of 6.7%. Some reports, most of 
which had a conditioning regimen different from ours, showed 
that tandem or sequential courses of HDCT were tolerable in 
their toxicity (11). In our study, no TRM was seen in the cases of 
tandem transplantation and no elevation of liver enzymes was 
shown with tandem transplantation compared to single trans-
plantation (Table 2). Rosenfeld et al. (15), who used the same 
conditioning regimens as our study at HDCT1 and HDCT2, re-
ported 6 TRMs (32%) which included 4 cases of VOD, 4 incidenc-
es of sepsis, and 1 myelodysplastic syndrome in 19 patients who 
underwent single or tandem transplantation for treatment of 
recurrent CNS tumors including 9 medulloblastoma. The rate of 
VOD was 11% at HDCT1 using CTE regimen, and 18% at HDCT2 
using CM regimen. The interval between HDCT1 and HDCT2 
was approximately 50 days. While our study showed a VOD inci-
dence rate similar to this report, the incidence was less at HDCT2 
(only one patient; 14%) compared to HDCT1 (23%). Our study 
recommended HDCT2 be delayed about 12 weeks from HDCT1 
according to reports that recommended 12 week intervals be-
tween HDCTs to prevent VOD (6). The longer intervals between 
HDCT1 and HDCT2 in our study may explain why we encoun-
tered less TRM and VOD at HDCT2 than reported by Rosenfeld. 
  This study was a multi-center trial; however, there were some 
limitations that should be addressed: first, it was impossible to 
compare the survival outcome between tandem and single 
transplantation because this study was not randomly compared; 
second, this study had a relatively short-term follow-up period 
so we could not formally evaluate long-term side effects using 
neuropsychological testing or quality of life assessment.
  In conclusion, this study shows acceptable survival outcomes 
compared to other recent studies that utilized HDCT/ASCT in 
pediatric patients with relapsed medulloblastoma. Tandem trans-
plantation is tolerated in pediatric patients with relapsed brain 
tumor. Patients with PD does not respond to tandem transplan-
tation even following several courses of intensive SC, but this 
treatment may be helpful to prolong the survival of patients 
whose status was PR pre-HDCT and achieved CR after HDCT1. 
Therefore, it is suggested that active application of tandem trans-
plantation, especially in patients with PR status prior to HDCT/
ASCT, will be helpful to prolong survival in cases of relapsed 
medulloblastoma. The role of tandem transplantation for those 
with a PR status reached after SC should be defined by a larger 
scale study.
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